aethlonmedical.com - יחס שווי חברה להכנסות AEMD

Aethlon Medical (AEMD) is protected by high regulatory barriers in the blood filtration niche thanks to its unique Hemopurifier. The technology physically removes pathogens and exosomes, complementing pharmacological cancer treatment. Growth is driven by government grants and successful clinical trials. The Enterprise Value to Sales ratio demonstrates the market reaction to news, where 0.00 forms the current metric value.
AEMD (Aethlon): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To stress-test positions, a pragmatic investor utilizes a metric that combines market capitalization and net debt divided by sales volume. The current 0.00 value regarding EV to revenue allows for a valuation of Aethlon Medical (AEMD) independent of macroeconomics, focusing attention on FDA regulatory risks and the progress of blood filter clinical trials when searching for consolidation zones.